Zim Laboratories Limited has informed the Exchange about EU GMP Inspection Outcome
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zim Laboratories' manufacturing facility in Kalmeshwar, Nagpur, was inspected by German and Portuguese regulatory authorities from 30 June to 4 July 2025 as part of the EU GMP compliance process. The inspection report dated 31 July 2025 found the facility non-compliant with EU GMP requirements, identifying 2 critical, 8 major, and 18 minor deficiencies. The company must submit a binding Corrective and Preventive Action (CAPA) plan within 4 weeks, after which a re-inspection will be conducted. The company has stated it remains committed to resolving the issues and achieving full compliance.
This is a negative development for shareholders — EU GMP non-compliance can restrict the company's ability to supply products to European markets, potentially affecting revenue and export earnings. The stock may face short-term pressure until clarity emerges on the CAPA implementation and re-inspection outcome.